文献速递脑血管病

白质高信号、急性期降压治疗与急性缺血性卒中功能结局

White Matter Hyperintensity, Immediate Antihypertensive Treatment, and Functional Outcome After Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2020-04-01

本研究为CATIS试验的次要分析,纳入303例有MRI数据的急性缺血性卒中患者,按Fazekas评分分为无-轻度(0-2分)和中-重度(3-6分)白质高信号。结果显示白质高信号严重程度与死亡或主要残疾风险增加相关,但早期降压治疗在不同严重程度白质高信号患者中均无显著获益。

要点

  • 白质高信号负担越高,急性缺血性卒中后死亡或主要残疾风险越高。
  • Fazekas评分每增加1分,14天或出院时功能结局的调整OR为1.25(95%CI 1.03-1.51)。
  • 早期降压治疗对不同程度白质高信号患者的临床结局均呈中性效应。

核心结论

  • 白质高信号负担较高的急性缺血性卒中患者死亡或主要残疾风险增加。
  • 早期降压治疗对不同程度白质高信号患者的临床结局均无显著影响。

研究设计与样本

  • 本研究为CATIS试验的次要分析,纳入303例有可用磁共振成像数据的急性缺血性卒中患者。
  • 采用Fazekas评分评估白质高信号严重程度,分为无-轻度(0-2分)和中-重度(3-6分)。

主要发现

  • 白质高信号严重程度与死亡或主要残疾风险增加显著相关。
  • Fazekas评分每增加1分,14天或出院时功能结局的调整OR为1.25(95%CI 1.03-1.51)。
  • Fazekas评分每增加1分,3个月功能结局的调整OR为1.39(95%CI 1.12-1.72)。
  • 降压治疗与白质高信号严重程度对14天或出院时及3个月功能结局均无显著交互作用(均P>0.1)。

关键数值与推荐

  • 功能结局定义为14天或出院时及3个月时死亡或主要残疾(改良Rankin量表评分≥3)。
  • 白质高信号严重程度采用Fazekas评分,无-轻度为0-2分,中-重度为3-6分。

临床怎么用

  • 对于急性缺血性卒中患者,白质高信号严重程度可用于辅助评估死亡或主要残疾的风险。
  • 早期降压治疗在不同白质高信号严重程度的急性缺血性卒中患者中未显示显著临床获益。

局限性

  • 本研究为次要分析,样本量有限(303例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- It remains unknown that whether white matter hyperintensity (WMH) severity influences the effect of antihypertensive treatment in acute ischemic stroke. We aimed to investigate the effects of early antihypertensive treatment on death and disability among patients with acute ischemic stroke according to WMH severities. Methods- This study was a secondary analysis of the data from CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). Severity of WMH was evaluated using Fazekas rating scale score among 303 participants with available magnetic resonance imaging data and was categorized into none-mild WMH (Fazekas score 0-2) and moderate-severe WMH (Fazekas score 3-6). Functional outcome was death or major disability (modified Rankin Scale score of ≥3) at 14 days or hospital discharge and within 3 months. Results- WMH severity was significantly associated with an increased risk of death or major disability. Each 1 score increase in Fazekas score was associated with an adjusted odds ratio (95% CI) of 1.25 (1.03-1.51) for 14 days or hospital discharge and 1.39 (1.12-1.72) for 3-month functional outcome. There were no significant interactions between antihypertensive treatment and WMH severity (both P>0.1) on functional outcome at 14 days or hospital discharge and within 3 months. The neutral effects of immediate antihypertensive treatment were observed both in patients with moderate-severe WMH and none-mild WMH. Conclusions- Participants with higher WMH burden had increased risk of death or major disability after acute ischemic stroke. Early antihypertensive treatment had a neutral effect on clinical outcomes among acute ischemic stroke patients with a variety of WMH severities. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01840072.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhu S, Qian S, Xu T, et al. White Matter Hyperintensity, Immediate Antihypertensive Treatment, and Functional Outcome After Acute Ischemic Stroke. Stroke. 2020. PMID: 32233741. doi:10.1161/STROKEAHA.119.028841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。